Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies
AbstractDespite advances in the treatment of metastatic, HER2+ breast cancer, the development of central nervous system metastases remains a therapeutic challenge. The challenge is amplified by the exclusion of patients with active brain metastases from many clinical trials. Initial HER2-targeted therapies, such as trastuzumab and pertuzumab, have shown limited efficacy for patients with brain metastases. In addition, the landscape of systemic therapy for HER2+ metastatic breast cancer is changing rapidly. In recent years, the development of small-molecule inhibitors in combination with chemotherapy has shown promise, thou...
Source: CNS Drugs - January 25, 2022 Category: Neurology Source Type: research
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“
(Source: CNS Drugs)
Source: CNS Drugs - January 11, 2022 Category: Neurology Source Type: research
Authors ’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”
(Source: CNS Drugs)
Source: CNS Drugs - January 11, 2022 Category: Neurology Source Type: research
Pharmacological Management of Apathy in Dementia
In conclusion, there are currently no US FDA-approved drugs that target apathy in dementia, so there is an on going need for the development of such drugs. (Source: CNS Drugs)
Source: CNS Drugs - January 10, 2022 Category: Neurology Source Type: research
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
(Source: CNS Drugs)
Source: CNS Drugs - December 27, 2021 Category: Neurology Source Type: research
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment
AbstractPediatric-onset multiple sclerosis (POMS) is a rare neuroinflammatory and neurodegenerative disease that has a significant impact on long-term physical and cognitive patient outcomes. A small percentage of multiple sclerosis (MS) diagnoses occur before the age of 18 years. Before treatment initiation, a careful differential diagnosis and exclusion of other similar acquired demyelinating syndromes such as anti-aquaporin-4-associated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody spectrum disorder (MOGSD) is warranted. The recent 2017 changes to the McDonald cri...
Source: CNS Drugs - December 23, 2021 Category: Neurology Source Type: research
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
ConclusionsThe results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy. These large effect sizes and low NNTs provide further evidence supporting the strength of the clinical response to pitolisant in the treatment of adults with narcolepsy.Clinical Trial RegistrationClinicalTrials.gov identifiers: NCT01067222 (February 2010), NCT01800045 (February 2013). (Source: CNS Drugs)
Source: CNS Drugs - December 21, 2021 Category: Neurology Source Type: research
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
AbstractThe cognitive dysfunction experienced by patients with schizophrenia represents a major unmet clinical need. We believe that enhancing synaptic function and plasticity by targeting kalirin may provide a novel means to remediate these symptoms. Karilin (a protein encoded by theKALRN gene) has multiple functional domains, including two Dbl homology (DH) guanine exchange factor (GEF) domains, which act to enhance the activity of the Rho family guanosine triphosphate (GTP)-ases. Here, we provide an overview of kalirin ’s roles in brain function and its therapeutic potential in schizophrenia. We outline how it mediate...
Source: CNS Drugs - December 20, 2021 Category: Neurology Source Type: research
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study
ConclusionsThe results of this study provide novel evidence that NK cells influence reconstitution of adaptive immune cells upon alemtuzumab and that patients with a successful response to alemtuzumab have an early immune reconstitution dominated by NK cells. (Source: CNS Drugs)
Source: CNS Drugs - December 11, 2021 Category: Neurology Source Type: research
Comment on: “Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively”
(Source: CNS Drugs)
Source: CNS Drugs - December 7, 2021 Category: Neurology Source Type: research
Authors ’ Reply to Ulrich: Comment on ‘Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively’
(Source: CNS Drugs)
Source: CNS Drugs - December 7, 2021 Category: Neurology Source Type: research
Nusinersen: A Review in 5q Spinal Muscular Atrophy
AbstractSurvival motor neuron 1 (SMN1), located on chromosome 5q, encodes the survival motor neuron (SMN) protein. A deletion or mutation inSMN1 results in a rare neuromuscular disorder: 5q spinal muscular atrophy (SMA). In such patients, SMN protein production relies solely onSMN2. Nusinersen (Spinraza®) is a modified antisense oligonucleotide approved for the treatment of 5q SMA. Administered intrathecally, it modifiesSMN2 pre-messenger RNA splicing, thereby increasing full-length SMN protein levels. Interim analyses from an ongoing phase II study suggest substantial clinical benefits with nusinersen initiation in presy...
Source: CNS Drugs - November 30, 2021 Category: Neurology Source Type: research
Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4 –5 Years with Attention-Deficit/Hyperactivity Disorder
ConclusionsIn children aged 4 –5 years with ADHD, following multiple once-daily administrations of SHP465 MAS 6.25 mg, the pharmacokinetic profile of plasmad-amphetamine andl-amphetamine was generally consistent among participants. Between-individual variability of plasmad-amphetamine andl-amphetamine steady-state exposure was low to moderate. SHP465 MAS was generally well tolerated in this study.Trial RegistrationClinicalTrials.gov, NCT03327402 (31 October, 2017). (Source: CNS Drugs)
Source: CNS Drugs - November 26, 2021 Category: Neurology Source Type: research
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
ConclusionsOnset of clinical response for excessive daytime sleepiness and/or cataplexy was generally observed within the first 2 –3 weeks of pitolisant treatment in patients with narcolepsy.ClinicalTrials.gov identifierNCT01067222 (February 2010), NCT01800045 (February 2013). (Source: CNS Drugs)
Source: CNS Drugs - November 25, 2021 Category: Neurology Source Type: research
Correction to: Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively
(Source: CNS Drugs)
Source: CNS Drugs - November 25, 2021 Category: Neurology Source Type: research
